Electroacupuncture for pain improvement in patients with postherpetic neuralgia : a single arm pilot study

Phase 1

• Conditions: Postherpetic neuralgia

• Registration Number: ITMCTR2100005386
• Lead Sponsor: Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

? Over 50 years old;
? Meet the diagnostic criteria of postherpetic neuralgia in the consensus of Chinese experts on the diagnosis and treatment of postherpetic neuralgia in 2016;
? Agree to receive acute analgesics;
? The average highest pain vas = 3 points within 1 week of the screening period;
? The patient signed the informed consent form and voluntarily participated in the trial.

Exclusion Criteria

? Previous neurolytic block or neurosurgical treatment;
? Pain unrelated to PHN;
? Have emotional disorders and need to take tricyclic antidepressants, mental and intellectual disorders;
? Complicated with serious primary diseases such as cardio cerebrovascular, liver, kidney and hematopoietic system, as well as other organic diseases such as tumors;
? Pregnant and lactating women or women who have fertility requirements in recent half a year;
? Poor blood glucose control, glycosylated hemoglobin = 8%;
? Anemia, untreated hypothyroidism or history of HIV infection and other immunodeficiency diseases and hepatitis B antigen or hepatitis C antibody positive history, active tuberculosis and other patients;
? Patients who had previously received acupuncture treatment;
? Belongs to the vulva and brachial plexus region and special types of herpes zoster, including PHN caused by eye, ear herpes zoster, contusion herpes zoster, herpes zoster free, herpes zoster meningitis or encephalitis, herpes zoster invading visceral nerve fibers, disseminated herpes zoster and others (herpes zoster with bullous, hemorrhagic, gangrenous and other manifestations);
? Participate in other clinical trials at the same time.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
VAS responder rate(=50%);